Propensity‐score matched analysis of the pathologic outcomes and survival benefits of neoadjuvant therapy in stage II–III anal adenocarcinoma
Journal of Surgical Oncology · 2023
DOI: 10.1002/jso.27313 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Surgical Oncology, 2023. Verfasst von Sameh Hany Emile und 5 weiteren Autor:innen. Beteiligte Einrichtung: Ellen Leifer Shulman and Steven Shulman Digestive Disease Center, Cleveland Clinic Florida, Weston, Florida, USA. Hauptthemen laut MEDLINE: Anus Neoplasms, Adenocarcinoma. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Anal adenocarcinomas are a rare condition which account for less than 10% of anal cancers. The present study aimed to assess the impact of neoadjuvant therapy on the clinical and pathologic outcomes and overall survival (OS) of patients with stage II–III anal adenocarcinomas after abdominoperineal resection (APR).
Methods
A retrospective cohort study of patients with anal adenocarcinoma in the US National Cancer Database (NCDB) (2010–2020) was conducted. Propensity‐score matching was used to compare patients who received neoadjuvant therapy (neoadjuvant therapy group) to the no‐neoadjuvant group. The primary outcome was 5‐year OS whereas secondary outcomes included conversion to open surgery, hospital stay, surgical margins, 30‐day mortality, 90‐day mortality, and 30‐day readmission.
Results
A total of 742 patients (56% male) with a mean age of 63.6 ± 12.4 years were included. A total of 214 patients in the neoadjuvant group were matched with 107 in the no‐neoadjuvant group. The mean OS was similar between the two groups (47.5 vs. 44.8 months, p = 0.253). Patients who received neoadjuvant therapy had a longer median time between diagnosis and surgery (151 vs. 54 days, p < 0.001), lower 90‐day mortality (1.9% vs. 6.7%, p = 0.046), more pT0 tumors (15.7% vs. 0%), less pT3‐4 tumors (28.4% vs. 36.4%, p = 0.001), less pN1‐2 tumors (22.9% vs. 34.7%, p < 0.001), and less lymphovascular invasion (16.2% vs. 40%, p < 0.001) than the no‐neoadjuvant group. Both groups had similar conversion rates, hospital stay, 30‐day mortality, 30‐day readmission, and positive surgical margins.
Conclusions
Neoadjuvant therapy before APR was associated with significant downstaging of anal adenocarcinomas and lower 90‐day mortality, yet similar OS to patients who were surgically treated without neoadjuvant treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Ellen Leifer Shulman and Steven Shulman Digestive Disease Center, Cleveland Clinic Florida, Weston, Florida, USA.
- Unit of Colorectal Surgery, Department of General Surgery, Mansoura University Hospitals, Mansoura, Egypt.
- Department of Surgery and Transplantation, Sheba Medical Center, Ramat-Gan, Israel.
- Department of General Surgery, Faculty of Medicine, Hadassah Medical Organization, Hebrew University of Jerusalem, Jerusalem, Israel.
ORCID-Profile: Sameh Hany Emile
Zitieren
APA
Emile, S. H., Horesh, N., Garoufalia, Z., Gefen, R., Zhou, P., & Wexner, S. D. (2023). Propensity‐score matched analysis of the pathologic outcomes and survival benefits of neoadjuvant therapy in stage II–III anal adenocarcinoma. Journal of Surgical Oncology. https://doi.org/10.1002/jso.27313
Vancouver
Emile SH, Horesh N, Garoufalia Z, Gefen R, Zhou P, Wexner SD. Propensity‐score matched analysis of the pathologic outcomes and survival benefits of neoadjuvant therapy in stage II–III anal adenocarcinoma. Journal of Surgical Oncology. 2023. doi:10.1002/jso.27313
BibTeX
@article{Emile2023,
author = {Emile, Sameh Hany and Horesh, Nir and Garoufalia, Zoe and Gefen, Rachel and Zhou, Peige and Wexner, Steven D},
title = {Propensity‐score matched analysis of the pathologic outcomes and survival benefits of neoadjuvant therapy in stage II–III anal adenocarcinoma},
journal = {Journal of Surgical Oncology},
year = {2023},
doi = {10.1002/jso.27313}
}
EUVIMED